 Brickell Biotech Inc NASDAQ: BBI has announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel for primary axillary hyperhidrosis excessive underarm sweating. The Company plans to file an FDA marketing application in mid-2022. 